title: Acute effects of ferumoxytol on regulation of renal hemodynamics and oxygenation.
abstract: The superparamagnetic iron oxide nanoparticle ferumoxytol is increasingly used as intravascular contrast agent in magnetic resonance imaging (MRI). This study details the impact of ferumoxytol on regulation of renal hemodynamics and oxygenation. In 10 anesthetized rats, a single intravenous injection of isotonic saline (used as volume control) was followed by three consecutive injections of ferumoxytol to achieve cumulative doses of 6, 10, and 41 mg Fe/kg body mass. Arterial blood pressure, renal blood flow, renal cortical and medullary perfusion and oxygen tension were continuously measured. Regulation of renal hemodynamics and oxygenation was characterized by dedicated interventions: brief periods of suprarenal aortic occlusion, hypoxia, and hyperoxia. None of the three doses of ferumoxytol resulted in significant changes in any of the measured parameters as compared to saline. Ferumoxytol did not significantly alter regulation of renal hemodynamics and oxygenation as studied by aortic occlusion and hypoxia. The only significant effect of ferumoxytol at the highest dose was a blunting of the hyperoxia-induced increase in arterial pressure. Taken together, ferumoxytol has only marginal effects on the regulation of renal hemodynamics and oxygenation. This makes ferumoxytol a prime candidate as contrast agent for renal MRI including the assessment of renal blood volume fraction.
authors.affiliation: Institut für Vegetative Physiologie, Center for Cardiovascular Research, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany.
authors.forename: Kathleen
authors.initials: K
authors.lastname: Cantow
authors.affiliation: Berlin Ultrahigh Field Facility, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Pohlmann
authors.affiliation: Institut für Vegetative Physiologie, Center for Cardiovascular Research, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany.
authors.forename: Bert
authors.initials: B
authors.lastname: Flemming
authors.affiliation: Institut für Vegetative Physiologie, Center for Cardiovascular Research, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany.
authors.forename: Fabienne
authors.initials: F
authors.lastname: Ferrara
authors.affiliation: Berlin Ultrahigh Field Facility, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
authors.forename: Sonia
authors.initials: S
authors.lastname: Waiczies
authors.affiliation: Physikalisch-Technische Bundesanstalt (PTB), Berlin, Germany.
authors.forename: Dirk
authors.initials: D
authors.lastname: Grosenick
authors.affiliation: Berlin Ultrahigh Field Facility, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
authors.forename: Thoralf
authors.initials: T
authors.lastname: Niendorf
authors.affiliation: Institut für Vegetative Physiologie, Center for Cardiovascular Research, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany.
authors.forename: Erdmann
authors.initials: E
authors.lastname: Seeliger
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D052203:Ferrosoferric Oxide / Q000494:pharmacology*; D006439:Hemodynamics / Q000187:drug effects*; D000860:Hypoxia / Q000378:metabolism / Q000503:physiopathology; D007668:Kidney / Q000187:drug effects* / Q000502:physiology*; D008297:Male; D010101:Oxygen Consumption / Q000187:drug effects*; D051381:Rats; D012079:Renal Circulation / Q000187:drug effects*
chemical_list: D052203:Ferrosoferric Oxide